Axos Financial Inc (AX) Stock News

Axon Enterprise (AXON) declined 1.34% to $407.80, underperforming the S&P 500's 1.11% loss. The stock has dropped 6.5% over the past month. Despite the recent weakness, the company maintains a Zacks Rank #1 (Strong Buy) rating with projected Q earnings of $1.94 per share (65.81% YoY growth) and full-year earnings of $7.88 per share (15.04% YoY growth). The stock trades at a Forward P/E of 52.44, above its industry average of 31.66.

Axon Enterprise has attracted investor attention despite a -6.5% return over the past month. The company is expected to report strong earnings growth of +65.8% year-over-year for the current quarter and +15% for the fiscal year. Revenue is projected to grow +31.6% in the current quarter. Axon received a Zacks Rank #1 (Strong Buy) rating, though it trades at a premium valuation (F grade) compared to peers.

Axalta Coating Systems (AXTA) has demonstrated a strong earnings-beat streak, surpassing estimates by an average of 11.38% over the last two quarters. With a positive Earnings ESP of +0.51% and a Zacks Rank #2 (Buy) rating, analysts expect the company to potentially beat consensus estimates again in its upcoming earnings report scheduled for October 29, 2026. Stocks combining positive Earnings ESP with a strong Zacks Rank historically beat estimates nearly 70% of the time.

Novavax has recently attracted investor attention with shares returning +18.4% over the past month, outperforming the S&P 500. However, the company faces significant headwinds including a projected loss of $0.38 per share for the current quarter and declining revenues expected to fall 66.4% for the current fiscal year. The stock received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term.

Axon Enterprise (AXON) closed at $417.31, up 2.79% in the latest session, outperforming the S&P 500. The company is projected to report earnings of $1.94 per share with 65.81% year-over-year growth and quarterly revenue of $935.35 million, up 31.62%. AXON holds a Zacks Rank #2 (Buy) rating with a Forward P/E of 51.5, trading at a premium to its industry average.

VERAXA Biotech announced its implementation of FDA-aligned New Approach Methodologies (NAMs) across its preclinical R&D programs to accelerate its BiTAC oncology pipeline while significantly reducing animal testing. The company presented data showing its BiTAC-TCE candidates demonstrated superior safety profiles and matched efficacy compared to traditional T cell engagers, with ex vivo studies using patient-derived xenograft models requiring only 10 mice versus 200+ for traditional studies.

Zacks equity research analysts featured five stocks in their October 7, 2026 analyst blog. SpaceX has outperformed its industry since going public, benefiting from reusable launch technology and Starlink expansion. Dell significantly outperformed the computer industry driven by AI infrastructure demand. KLA outperformed its sector due to AI-driven semiconductor demand and process-control intensity. AXIL Brands underperformed its industry facing tariff pressures and elevated marketing costs. Optex Systems underperformed the aerospace-defense sector due to margin pressure and weak cash flow, though it benefits from a strong backlog.

Novavax stock jumped 20.1% following renewed investor interest in vaccine stocks, triggered by pneumonia-related concerns in Russia and positive results from Vaxcyte's pneumococcal vaccine. The company benefits from COVID-19 vaccine approvals and a Sanofi partnership. However, Novavax faces declining revenues and continued quarterly losses, though earnings estimate revisions have improved significantly.

Axon Enterprise has been trending on Zacks.com's most searched stocks list. The stock has declined 19.1% over the past month, significantly underperforming the S&P 500. While the company shows strong revenue growth forecasts (+32.4% for current fiscal year) and positive earnings revisions, it carries a Zacks Rank #3 (Hold) rating and trades at a premium valuation with an F grade on value metrics, suggesting it may perform in line with the broader market in the near term.

Byron Medical has launched Zumax, a range of advanced surgical microscopes across Australia and New Zealand. The product line includes three tiers (OMS 2050, OMS 2380 R2, and OMS 3000) featuring true-colour illumination, integrated 4K documentation, ergonomic design, and smart digital integration for dental practices.

AXT, a semiconductor materials supplier, has earned a Momentum Style Score of A and a Zacks Rank #1 (Strong Buy) rating. The stock has significantly outperformed its industry and the broader market, gaining 12.72% over the past week and 1406.54% over the past year. Recent earnings estimate revisions have been positive, with consensus estimates increasing from $0.46 to $0.86 in the past 60 days, supporting the bullish outlook.

Hitachi Rail announced the launch of 'Enhanced by HMAX', a digital asset management platform embedding AI and real-time data capabilities across rolling stock, signaling, infrastructure and operations. The company committed to equipping all new rolling stock with HMAX sensor technology from 2027, with approximately 2,500 trains currently equipped and expanding to 3,500 in coming years. The platform enables predictive maintenance and operational optimization, with real-world deployments showing 15% reductions in maintenance costs and energy consumption.

Delta Air Lines announced its largest-ever summer schedule for 2027 at Los Angeles International Airport, planning over 200 daily departures to nearly 70 destinations. The expansion includes new nonstop routes to Monterey and Philadelphia, increased frequencies to seven U.S. cities, and $2.3 billion in airport infrastructure investments including premium lounges and enhanced onboard offerings.

A comparison of two insurance stocks shows that Münchener Rückversicherungs-Gesellschaft (MURGY) presents a better value opportunity than Axa Sa (AXAHY). MURGY has a higher Zacks Rank (#2 Buy vs #3 Hold), lower forward P/E ratio (9.68 vs 10.73), better PEG ratio (1.89 vs 5.04), and a superior Value grade (B vs C), making it the more attractive option for value investors.

Novavax stock closed at $10.11, up 1.1% and outpacing the S&P 500's 0.17% gain. However, the vaccine maker faces headwinds with projected quarterly revenue down 39.01% year-over-year and full-year revenue expected to decline 68.15%. The stock holds a Zacks Rank #3 (Hold) rating, with EPS estimates falling 7.86% over the past month.

AXT, a semiconductor substrate manufacturer, is positioned as a critical supplier for AI data-center optical interconnects, particularly in indium phosphide (InP) substrates. The company reported record Q2 2026 revenue of $47.6M (up 165% YoY) with 44.9% gross margins and a 170% EPS beat. With a >$100M backlog, planned capacity expansions to $35M quarterly by end-2026 and $65-70M by 2027/early 2028, and progression toward 6-inch wafers, AXT is transitioning from a cyclical substrate maker into a critical AI infrastructure supplier. However, risks include potential slowdown in AI optical spending, China export controls, and margin sustainability.

AXT, Inc. is diversifying its revenue streams beyond China, with Europe revenues surging 302.3% and other Asian markets showing strong growth in the first half of 2026. However, the company faces intensifying competition from Coherent and Lumentum in the indium phosphide (InP) substrate market as both rivals expand their optical connectivity capabilities. Despite premium valuation, AXT holds a Zacks Rank #1 (Strong Buy) with 2026 earnings expected at 86 cents per share.

A comparison of Virtu Financial (VIRT) and American Express (AXP) from the Financial - Miscellaneous Services sector reveals that VIRT is the more attractive value investment. VIRT has a Zacks Rank of #2 (Buy) versus AXP's #3 (Hold), with superior valuation metrics including a forward P/E of 8.67 compared to AXP's 18.36, a PEG ratio of 0.37 versus 1.38, and a P/B ratio of 4.06 versus 6.4. VIRT received a Value grade of B while AXP received a C.

Novavax (NVAX) closed at $9.42, up 1.29%, outperforming the S&P 500's 0.86% gain. The stock has appreciated 14.25% over the past month. However, the company faces headwinds with projected quarterly EPS of -$0.22 and revenue expected to decline 39.01% year-over-year. Annual projections show -$0.47 EPS and 68.15% revenue decline. Novavax holds a Zacks Rank of #3 (Hold), with consensus EPS projections down 10.12% in the past 30 days.

AXT Inc. shares have declined 22% over three months but remain up 322.4% year-to-date. Despite the pullback, strong demand for indium phosphide (InP) substrates for AI data-center optical applications, aggressive capacity expansion plans, and long-term customer supply agreements support a bullish outlook. The stock is rated Zacks Rank #1 (Strong Buy), though it trades at a premium valuation of 34.85X P/S ratio.

A comparison of two Financial - Investment Management stocks reveals that Patria Investments (PAX) presents a better value opportunity than KKR & Co. Inc. (KKR). PAX holds a Zacks Rank #2 (Buy) with a forward P/E of 8.10 and Value grade of A, while KKR has a Zacks Rank #3 (Hold) with a forward P/E of 16.49 and Value grade of D. PAX demonstrates stronger earnings estimate revisions and more attractive valuation metrics across multiple indicators.

While Axon Enterprise (AXON) has a strong average brokerage recommendation of 1.38 (Strong Buy/Buy) from 20 firms, Zacks cautions investors against relying solely on broker ratings due to their positive bias. The company's Zacks Rank #3 (Hold) rating, based on unchanged earnings estimates of $7.88, suggests the stock may perform in line with the broader market in the near term, warranting a more cautious approach than the bullish broker consensus.

VERAXA Biotech AG announced the appointment of Raju Willener as Chief Financial Officer, effective immediately. Willener brings over 30 years of experience in global capital markets and biopharmaceutical finance. The appointment comes as VERAXA advances its BiTAC® platform and oncology pipeline toward clinical development.

Axsome Therapeutics has dosed the first patient in the phase III SUMMIT study evaluating AXS-05 for smoking cessation. The randomized, double-blind, placebo-controlled trial will compare AXS-05 against bupropion and placebo over 12 weeks, with smoking abstinence as the primary endpoint. Axsome's lead drug Auvelity continues to drive strong revenue growth, generating $333 million in H1 2026 (up 54.2% YoY), while the company's diversified portfolio includes Sunosi and newly launched Symbravo.

IMAX stock reached an all-time high driven by the exceptional success of Christopher Nolan's The Odyssey, which became the highest-grossing IMAX release ever. The company reported strong H1 2026 results with 12% revenue growth and 65% earnings growth, while installing 38 premium theater systems at its fastest second-quarter pace in a decade. Analyst Steve Frankel expects results to exceed Wall Street estimates in H2 2026, bolstered by The Odyssey's continued performance and the upcoming Dune: Part Three release.

IMAX Corporation's Chief Technology Officer Pablo Calamera sold 15,000 common shares on August 20, 2026, reducing his direct stake by 26% at a weighted average price of $52.41 per share. The sale occurred as IMAX stock surged 105% over the trailing 12-month period, driven by strong Q2 earnings with 12% revenue growth and Christopher Nolan's 'The Odyssey' becoming the highest-grossing IMAX film ever. Despite the sale, Calamera retains 43,012 common shares and 20,840 RSUs, maintaining significant alignment with shareholder interests.

IMAX stock surged 4.33% on Monday after announcing that Christopher Nolan's 'The Odyssey' became the highest-grossing IMAX release of all time with $289 million in ticket sales. The film continues to sell out weeks in advance with nearly $40 million in presales, and IMAX expects this to be its best year ever at the global box office.

The FAA finally certified Boeing's 737 MAX 7 on Monday, seven years after the original 2019 target. The certification clears the way for Boeing to deliver approximately 30 completed aircraft in storage. While the approval is significant for unlocking revenue, the stock's 8% rally was also driven by cheaper oil and a BNP Paribas upgrade. The analyst suggests most of the positive impact is already priced in, with meaningful revenue impact expected in 2027.

Bernstein Liebhard LLP has launched investigations into potential breaches of fiduciary duty by directors and officers at CarMax, Inc., Capricor Therapeutics, Inc., and Calix, Inc. The firm is seeking to determine whether company leadership acted in shareholders' best interests and is encouraging affected shareholders to contact them for legal consultation.

US FAA certifies Boeing 737 MAX 7 in win for planemaker  Reuters